Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_assertion type Assertion NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_head.
- NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_assertion description "[After two to three passages, Met was downregulated in 37% of NFH-OSE cultures but persisted in 100% of FH-OSE cultures and ovarian cancer lines, like other epithelial differentiation markers that are stabilized in FH-OSE and neoplasia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_provenance.
- NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_assertion evidence source_evidence_literature NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_provenance.
- NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_assertion SIO_000772 11313876 NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_provenance.
- NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_assertion wasDerivedFrom befree-2016 NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_provenance.
- NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_assertion wasGeneratedBy ECO_0000203 NP315356.RAV1CvbFT_0jswjCpUKLBhUokdDwLY1JZR8DV5o1eQLUY130_provenance.